BioDrain Presents Growing Sales Outlook at the National Investment Banking Association Conference in Boston
Outlook Analysis Attached
(firmenpresse) - MINNEAPOLIS, MN -- (Marketwire) -- 08/22/11 -- BioDrain Medical, Inc. (OTCBB: BIOR) (OTCQB: BIOR), producer of the FDA cleared Streamway® System for automated surgical fluid disposal, today announced that Alan Shuler, the Company's Secretary and Acting Chief Financial Officer, presented additional details of the Company's growing sales outlook at the National Investment Banking Association (NIBA) Conference that was held at the Omni Parker House in Boston on August 17-19, 2011.
Addressing an audience of more than 70 investors on August 18, Mr. Shuler included a newly updated activity report describing the rapidly expanding sales opportunities for BioDrain's unique, patented, FDA approved Streamway System. The report, which was included as a slide in the Company's investor presentation and included below within this release, identifies near-term opportunities from hospitals across the nation with sales potential of over $3 million and long-term opportunities representing sales potential of over $7 million. These figures derive from potential orders for Streamway System units recently identified by our newly expanded sales rep team and the expected recurring revenues from consumables that accrue to each unit. (Hospitals are identified here according to location only.)
"I was excited to present our latest developments in commercializing BioDrain's Streamway System to NIBA's audience of investment banking, corporate finance and investment brokerage firms," declared Mr. Shuler. "Our newly expanded sales rep force is aggressively increasing our ability to demonstrate Streamway's continuous, automated and cost effective process to an expanding number of hospitals and surgical centers. As these medical centers discover the safety, low cost, improved environmental impact and efficiency of the Streamway System, we anticipate a corresponding conversion of these demonstrations into purchase orders, and we are preparing to meet the demand. The additional slide to our investor presentation provides an overview of the opportunities that are now in our sales pipeline."
BioDrain Medical, Inc. has a fully automated, patented, FDA cleared, surgical fluid disposal system that virtually eliminates operating room workers' exposure to blood, irrigation fluid and other potentially infectious fluids found in the surgical environment. Today's manual surgical fluid handling methods of hand-carrying filled surgical fluid canisters and emptying these canisters is an exposure risk and an antiquated approach to the handling of surgical fluid waste. BioDrain's Streamway System fully automates the collection, measurement and disposal of surgical fluids resulting in: 1) reducing overhead costs to hospitals and surgical centers, 2) improving the Occupational State and Health Association (OSHA) and other regulatory compliance, and 3) improving the efficiency of the operating room (and thereby making surgeries more profitable).
BioDrain's Streamway System is eco-friendly as it contributes to cleaning up the environment. Currently, approximately 50 million bloody, potentially disease infected canisters go to landfills annually in the United States. These tainted canisters can remain in landfills for years to come. With the installation of BioDrain's Streamway System, the number of canisters can be significantly reduced. BioDrain Medical, Inc. makes the operating room and our environment safer, cleaner, and better. BioDrain products are currently being represented by independent professional sales representatives that cater to the needs of hospitals and ambulatory surgical centers across the country. For additional information, please visit: .
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the company's ability to implement its long range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position. See the company's most recent Quarterly Report on Form 10-Q and related 8-K filings.
Stanley Wunderlich
Consulting for Strategic Growth 1 Ltd.
Tel: 800-625-2236 ext. 7770
Email:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.08.2011 - 12:00 Uhr
Sprache: Deutsch
News-ID 57674
Anzahl Zeichen: 0
contact information:
Town:
MINNEAPOLIS, MN
Kategorie:
Hospitals, Facilities and Providers
Diese Pressemitteilung wurde bisher 249 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BioDrain Presents Growing Sales Outlook at the National Investment Banking Association Conference in Boston"
steht unter der journalistisch-redaktionellen Verantwortung von
BioDrain Medical Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
